As per the research report, the size of the Asia Pacific Nanomedicine Market is valued at USD 22.67 billion in 2019 and is projected to grow at a CAGR of 16.3%, to reach USD 48.24 billion by 2024 during the forecast period 2019-2024.
The application of various techniques and instruments of nanotechnology in the field of medicine is known as Nanomedicine. It involves using nanoscale materials to diagnose diseases, drug delivery and other functions. Nanomedicine has the potential to revolutionize medicine in the future.
One of the major challenges for the use of nanoparticles in medicine is to make the materials as biocompatible. Applications of nanocapsules in drug delivery have shown excellent results in chemotherapy. Nanomedicine enables great precision in both diagnostics and therapeutics which is not possible before. Pipeline products which are being developed with the intention to target cancerous tumors are expected to boost the nanomedicine market.
Increasing applications of nanomaterials such as nanocapsules and nanotubes in drug delivery systems, growing number of cancer and cardiovascular diseases, increasing public and private investments on research activities in nanomedicine and advancements in the biodegradable nanoparticles are the major factors propelling the growth of nanomedicine market. However, unfavorable approval processes possibility for unintended risks during therapies and high cost of treatment using nanomedicine are hindering the market growth.
This research report segmented and sub-segmented into the following categories:
There is a high incidence of cancer and cardiovascular diseases in Asia pacific due to the large geriatric population in this region. Growing health awareness and increasing healthcare expenditure are also driving the market growth. China leads the nanomedicine market in this region.
The Top companies leading in the APAC Nanomedicine Market profiled in the report are Johnson & Johnson, Merck & Co, Pfizer, Abbott Laboratories, GE Healthcare, Celgene Corporation, Nanosphere, Inc, Gilead Sciences, Hoffmann-La Roche, Nanospectra Biosciences, and Arrowhead Pharmaceuticals.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Diagnostic Imaging
5.1.3 Regenerative Medicine
5.1.4 Drug Delivery
5.1.5 Implants
5.1.6 Vaccines
5.1.7 Others
5.1.8 Y-o-Y Growth Analysis, By Product
5.1.9 Market Attractiveness Analysis, By Product
5.1.10 Market Share Analysis, By Product
5.2 Disease Type
5.2.1 Introduction
5.2.2 Cardiovascular Diseases
5.2.3 Neurological Diseases
5.2.4 Ophthalmological Diseases
5.2.5 Infectious Diseases
5.2.6 Immunological Diseases
5.2.7 Orthopedic Disorders
5.2.8 Oncological Diseases
5.2.9 Others
5.2.10 Y-o-Y Growth Analysis, By Disease Type
5.2.11 Market Attractiveness Analysis, By Disease Type
5.2.12 Market Share Analysis, By Disease Type
5.3 Nanomolecule Type
5.3.1 Introduction
5.3.2 Nanotubes
5.3.3 Nanoparticles
5.3.4 Nanodevices
5.3.5 Nanoshells
5.3.6 Others
5.3.7 Y-o-Y Growth Analysis, By Nanomolecule Type
5.3.8 Market Attractiveness Analysis, By Nanomolecule Type
5.3.9 Market Share Analysis, By Nanomolecule Type
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Disease Type
6.1.3.4 By Nanomolecule Type
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Disease Type
6.1.4.4 By Nanomolecule Type
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Disease Type
6.1.5.4 By Nanomolecule Type
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Johnson & Johnson
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Merck & Co
8.3 Pfizer
8.4 Abbott Laboratories
8.5 GE Healthcare
8.6 Celgene Corporation
8.7 Nanosphere, Inc
8.8 Gilead Sciences
8.9 Hoffmann-La Roche
8.10 Nanospectra Biosciences
8.11 Arrowhead Pharmaceuticals
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
